Why Cutting Out a Keloid Alone Often Makes It Worse, and What Adjuvant Therapy Actually Does

One of the most common questions in keloid care sounds simple: if the scar is the problem, why not just cut it out? The answer sits in the biology of how keloids form in the first place. Understanding it explains why surgeons who treat keloids seriously almost never operate without a follow-up plan, and why patients who receive excision alone are often trading one keloid for a larger one.

A keloid is not a lump, it is a behavior. Normal wound healing follows a sequence: inflammation, proliferation, then remodeling, where excess collagen is broken down and the scar flattens over months. In keloid-prone skin, fibroblasts in the wound bed stay switched on. They overproduce type I and type III collagen, respond abnormally to signaling molecules such as transforming growth factor beta 1, and resist the programmed cell death that normally winds healing down. The visible scar is the output of that behavior. Cutting the scar off does not remove the behavior, because the fibroblasts at the wound edges and in the surrounding dermis carry the same tendencies.

Excision creates a fresh, larger wound in the same reactive tissue. When a keloid is removed, the incision line is typically longer than the original injury that triggered the keloid. The body then mounts a new healing response, often in skin under tension, in a body region already known to be high risk, in a patient already known to be a keloid former. Reported recurrence rates for excision alone vary across studies but commonly fall in the range of 45 to 100 percent. Worse, the recurrent keloid can extend beyond the original footprint because the surgical wound was bigger than the initial trigger.

Adjuvant therapy targets the healing response, not the scar. This is the conceptual shift that matters. The excision removes bulk. The adjuvant treatment is aimed at the weeks that follow, when fibroblasts decide whether to remodel normally or overproduce again. The main evidence-supported options work through different mechanisms.

Postoperative radiation is generally considered the most effective adjuvant for high-risk or previously recurrent keloids. Low-dose superficial radiation or brachytherapy, usually delivered within 24 to 72 hours after surgery, damages the DNA of rapidly dividing fibroblasts and endothelial cells in the fresh wound. Because these cells are proliferating quickly right after excision, they are selectively vulnerable while surrounding tissue is relatively spared. Published series report recurrence rates dropping to roughly 10 to 30 percent depending on dose, site, and follow-up length. The tradeoffs are real: pigment changes, delayed healing in some patients, and a very small theoretical long-term malignancy risk that clinicians weigh carefully, particularly in younger patients and near the thyroid or breast.

Intralesional corticosteroids, most often triamcinolone acetonide, are injected into the wound edges at surgery and then at intervals afterward, commonly every 3 to 6 weeks for several sessions. Steroids suppress inflammatory signaling, reduce fibroblast proliferation, and inhibit collagen synthesis while increasing collagenase activity. They are widely available and inexpensive, but recurrence rates with steroids alone after excision remain meaningful, and side effects include skin thinning, visible small blood vessels, and hypopigmentation, which matters especially in darker skin tones where keloids are more common.

5-fluorouracil, an antimetabolite, is sometimes combined with triamcinolone in injections. It interferes with fibroblast DNA synthesis and appears to blunt TGF-beta driven collagen production. Several comparative studies suggest the combination outperforms steroid alone with fewer atrophy-related side effects, though injection pain and temporary darkening at the site are common.

Pressure therapy and silicone play supporting roles. Continuous pressure, classically used on earlobe keloids with custom clips or earrings after excision, is thought to induce local tissue hypoxia and mechanical signaling changes that reduce collagen deposition. It requires months of consistent wear, often 12 or more hours daily for 6 to 12 months. Silicone gel sheeting hydrates the stratum corneum and may modulate fibroblast activity through occlusion, with modest but real supportive evidence when used early and consistently.

Mechanical tension is the quiet variable. Keloids favor high-tension zones: chest, shoulders, upper back, jawline. Surgical technique that minimizes tension on the closure, orients incisions along relaxed skin lines, and avoids wound edge trauma reduces the mechanical signaling that drives fibroblasts toward overproduction. Taping or tension-offloading dressings for weeks after surgery extend that benefit.

What this means practically. If you are considering excision of a keloid, the most important question is not about the surgery itself but about the plan for the 3 to 12 months afterward. A reasonable plan usually includes at least one adjuvant, chosen based on the keloid's location, size, your history of recurrence, and your tolerance for the side effect profile. Excision alone is rarely a complete treatment. It is the opening move in a longer strategy, and evaluating any proposed treatment through that lens is the single most useful habit a keloid patient can adopt.